Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial

Highlight

– Dapagliflozin treatment improved MASH activity scores and fibrosis outcomes significantly compared to placebo.
– MASH resolution without fibrosis worsening was nearly threefold higher in the dapagliflozin group.
– Fibrosis improvement occurred in 45% of treated patients without increased adverse events.
– The treatment was well tolerated, with very low rates of discontinuation due to adverse events.

Study Background and Disease Burden